Therapeutic Abstention and Surveillance of Intra-epithelial Histological Lesions of High Grade Cervical CIN2 (Cervical Intraepithelial Neoplasia Grade 2). SUIVICIN (SUIVICIN)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jean-Luc Brun, MD, PhD
- Phone Number: 335 56 79 59 85
- Email: jean-luc.brun@chu-bordeaux.fr
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- CHU Bordeaux
-
Contact:
- Jean-Luc Brun, MD, PhD
- Phone Number: 335 56 79 59 85
- Email: jean-luc.brun@chu-bordeaux.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- CIN2 confirmed by biopsy, age between 18 and 39 years,
- satisfactory colposcopy identifying the junction and the lesion,
- affiliated person or beneficiary of a social security scheme,
- having given their oral agreement and authorization to the processing of their data.
Exclusion Criteria:
- Pregnancy in progress,
- history of conization,
- atypical or atypical glandular cells or cancer incidentally discovered during smear,
- prophylactic vaccination against HPV,
- active systemic infection requiring treatment, history of HIV infection, congenital or acquired immunodepression,
- long-term treatment with corticosteroids or immunosuppressants, placement under safeguard of justice,
- non-compliance with protocol requirements, in particular a supposed lack of compliance with long-term follow-up
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
CIN 2 women
Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
|
Non-interventional monocentric prospective study taking place at the Bordeaux University Hospital where women with a CIN2 meeting the eligibility criteria will benefit from abstention from treatment and surveillance for at least 2 years
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of spontaneous regression of CIN2 at 2 years
Time Frame: 2 years
|
Rate of spontaneous regression of CIN2 at 2 years, either complete (disappearance of the lesion) or partial (<lesions of low grade LSIL).
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of regression of CIN2 at 4 years
Time Frame: 4 years
|
rate of regression of CIN2 at 4 years in women who responded to the main rate of regression of CIN2 at 4 years in women who responded to the main objective (disappearance of the lesion or lesions <low grade LSIL) and monitored for 2 more years
|
4 years
|
|
4-year regression rate of CIN2 that persisted for 2 years
Time Frame: 1, 2, 3 and 4 years
|
evaluate the 4-year regression rate of CIN2 that persisted for 2 years in women who had not been treated with conization
|
1, 2, 3 and 4 years
|
|
HPV viral expression
Time Frame: 1, 2, 3 and 4 years
|
Binary criteria: yes / No
|
1, 2, 3 and 4 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Pathologic Processes
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Disease Attributes
- Infections
- Virus Diseases
- Uterine Diseases
- Genital Diseases, Female
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- DNA Virus Infections
- Genital Neoplasms, Female
- Precancerous Conditions
- Uterine Cervical Diseases
- Uterine Neoplasms
- Tumor Virus Infections
- Uterine Cervical Neoplasms
- Papillomavirus Infections
- Uterine Cervical Dysplasia
Other Study ID Numbers
Other Study ID Numbers
- CHUBX 2019/03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.